Report #2853655

Received Aug 11, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: MA
Recovered: Unknown
Vaccinated: Aug 5, 2025
Onset: Aug 5, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Late second dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose on MAR-2022). On 05-AUG-2025, the patient received the 2nd dose of Shingrix. On 05-AUG-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 05-AUG-2025 On 5 August 2025, a patient called to get guidance on the Shingrix vaccine series. He mentioned he had the first shingles dose back in March 2022 and received the second dose on 5 August 2025 which led to drug dose administration interval too long The patient wanted to know what about the effectiveness of vaccine.